Leukocyte Count as an In‐Hospital Prognostic Indicator in Acute Pulmonary Embolism: Evidence From a Registry Study and Genetic Analyses
Respirology · 2025
DOI: 10.1002/resp.70171 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Respirology, 2025. Verfasst von Shuai Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Pulmonary Embolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding and Elite Medical Professionals Project of China-Japan Friendship Hospital, The National Key R&D Program of China, Ministry of Science and Technology of China, CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Background and Objective As a well‐established inflammatory biomarker, leukocyte count is associated with higher mortality in acute pulmonary embolism (PE). We aimed to confirm the prognostic utility of leukocyte count and its integration with simplified Pulmonary Embolism Severity Index (sPESI) for predicting all‐cause hospital mortality in acute PE.
Methods
Data derived from a national, multicentre and prospective registry including patients with acute PE were analysed to develop and validate an in‐hospital mortality prediction model incorporating leukocyte count and sPESI. Mendelian Randomisation (MR) was performed to assess the relationship between leukocyte count and mortality.
Results
A total of 7312 PE patients were stratified into three groups based on admission leukocyte count: < 4 × 10 9 /L ( n = 301, 4.1%), (4–10) × 10 9 /L ( n = 5074, 69.4%) and > 10 × 10 9 /L ( n = 1937, 26.5%). Patients with leukocytosis exhibited a higher prevalence of anaemia, thrombocytopenia, hypoxemia, cardiac and renal injury, as well as haemodynamic instability. The in‐hospital all‐cause mortality was 3.0%, 2.3% and 6.4% ( p < 0.001) across the three groups, respectively. The area under the curve (AUC) of sPESI was 0.719 (95% CI 0.681–0.756, p < 0.001), increasing to 0.738 (95% CI 0.701–0.775, p < 0.001) when combined with leukocyte count groups. The prognostic value of leukocyte count and its combination with sPESI was validated in a cohort with 7660 PE patients. MR analysis demonstrated that elevated leukocyte counts increased mortality risk (OR = 1.11, 95% CI 1.00–1.24, p = 0.047).
Conclusion
Admission leukocyte count enhances the prognostic accuracy of sPESI for in‐hospital all‐cause mortality in PE. Leukocyte count could serve as a potential biomarker for identifying PE patients at increased mortality risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
- China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
- Department of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, China.
- Department of Pulmonary and Critical Care Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Pulmonary and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Shuai Zhang, Dingyi Wang, Jun Wan
Förderung
- National High Level Hospital Clinical Research Funding and Elite Medical Professionals Project of China-Japan Friendship Hospital
- The National Key R&D Program of China, Ministry of Science and Technology of China
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- The Fund of the National Key Research and Development Program of China
Zitieren
APA
Zhang, S., Li, H., Chen, Y., Xu, X., Ji, Y., Yang, Y., Yi, Q., Chen, H., Hu, X., Liu, Z., Mao, Y., Zhang, J., Shi, J., Lei, J., Wang, D., Zhang, Z., Zhang, Y., Gao, Q., Xie, W., …, & China pUlmonary Thromboembolism REgistry Study (CURES) Investigators (2025). Leukocyte Count as an In‐Hospital Prognostic Indicator in Acute Pulmonary Embolism: Evidence From a Registry Study and Genetic Analyses. Respirology. https://doi.org/10.1002/resp.70171
Vancouver
Zhang S, Li H, Chen Y, Xu X, Ji Y, Yang Y, et al. Leukocyte Count as an In‐Hospital Prognostic Indicator in Acute Pulmonary Embolism: Evidence From a Registry Study and Genetic Analyses. Respirology. 2025. doi:10.1002/resp.70171
BibTeX
@article{Zhang2025,
author = {Zhang, Shuai and Li, Haobo and Chen, Yinong and Xu, Xiaomao and Ji, Yingqun and Yang, Yuanhua and Yi, Qun and Chen, Hong and Hu, Xiaoyun and Liu, Zhihong and Mao, Yimin and Zhang, Jie and Shi, Juhong and Lei, Jieping and Wang, Dingyi and Zhang, Zhu and Zhang, Yunxia and Gao, Qian and Xie, Wanmu and Wan, Jun and Fang, Baomin and Zhai, Zhenguo and Wang, Chen and China pUlmonary Thromboembolism REgistry Study (CURES) Investigators, China pUlmonary Thromboembolism REgistry Study (CURES) Investigators},
title = {Leukocyte Count as an In‐Hospital Prognostic Indicator in Acute Pulmonary Embolism: Evidence From a Registry Study and Genetic Analyses},
journal = {Respirology},
year = {2025},
doi = {10.1002/resp.70171}
}
EUVIMED